Personalized Skin Cancer Therapy, Despite FDA Delay: Analysts Show Confidence In Iovance Biotherapeutics Therapy
Portfolio Pulse from Vandana Singh
The FDA has extended the review period for Iovance Biotherapeutics Inc's marketing application for lifileucel, a therapy for advanced melanoma. The new target action date is February 24, 2024. Despite the delay, analysts from HC Wainwright and Mizuho maintain their confidence in the approval of the therapy and reaffirm the Buy rating for IOVA stock. IOVA shares are up 18.30% at $5.49.
September 15, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Despite the FDA's delay in reviewing Iovance's lifileucel therapy, analysts remain confident in its approval and maintain a Buy rating for the company's stock. IOVA shares are up 18.30%.
The FDA's delay in reviewing Iovance's therapy could have been a negative factor for the company's stock. However, the continued confidence from analysts and their reaffirmation of a Buy rating for IOVA stock indicates a positive outlook. This is further supported by the increase in IOVA's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100